Mounjaro on the NHS in Northern Ireland: Access, Eligibility and What Comes Next

What NICE TA1026 covers — and why Northern Ireland isn't included

In December 2024, NICE published Technology Appraisal 1026, recommending tirzepatide for adults with a BMI of 35 or above alongside at least one weight-related condition such as high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance, typically 2.5 kg/m² below the standard figures. NICE TA1026 is an England recommendation; it directs NHS England commissioning and the phased GP rollout that began in June 2025.

Health is a devolved matter in the UK. Northern Ireland's Department of Health commissions medicines separately, as do Scotland and Wales. When a NICE technology appraisal is published, the devolved administrations review it and decide whether to adopt, adapt or not follow it. That process takes time, and as of summer 2026 Northern Ireland had not announced a funded NHS pathway for Mounjaro (tirzepatide) in weight management. Anyone currently exploring NHS Mounjaro access in Northern Ireland in detail will find the same answer: no confirmed funded route yet.

The clinical trial evidence that underpinned the NICE decision is substantial. SURMOUNT-1, a 72-week trial involving 2,539 adults with obesity, showed average body-weight reductions of around 20–21% at the 15 mg dose. That evidence base sits behind every devolved review too, Northern Ireland's health commissioners will work from the same data when a decision is made.

How the NHS rollout in England differs from Northern Ireland's position

For readers who've been following the NHS England tirzepatide rollout, it's worth being clear about what the phased system actually means there, so the contrast with Northern Ireland is legible. From June 2025, NHS England began making tirzepatide available to patients with a BMI of 40 or above who also have four or more of the five qualifying conditions. A second cohort, covering BMI 35–39.9 with four or more conditions, opened in June 2026. Even in England, eligibility is strict, and GP practices opt into the scheme voluntarily, so availability varies by area.

Northern Ireland currently has none of that infrastructure for tirzepatide. There's no equivalent GP contract amendment and no announced specialist service pathway for this medicine. Patients in Northern Ireland who qualify on BMI and comorbidity grounds would, in England, now be eligible, but geography matters here in a very direct sense.

For a broader look at how NHS access compares across the four nations, the full NHS Mounjaro overview sets out the differences plainly. The short version: Northern Ireland sits closest to Scotland in terms of tirzepatide access, both still awaiting a confirmed funded route. For Scotland-specific detail, NHS Mounjaro in Scotland covers the picture there.

Buying Mounjaro online in Northern Ireland: the legal private route

Mounjaro is a Prescription-Only Medicine. That means it can only be legally supplied following a clinical assessment by a registered prescriber who determines it is suitable for the individual, this applies everywhere in the UK, including Northern Ireland. There is no legal shortcut. Anyone offering tirzepatide without a prescription is operating outside UK law, and the MHRA has warned repeatedly about counterfeit and illegally traded weight-loss pens, with enforcement operations seizing around 20 million doses (approximately £45 million street value) of illegally traded medicines in 2025 alone. Discount codes attached to unknown online sellers are a red flag, not a deal.

The safe and legal route for people in Northern Ireland is a private prescription through a pharmacy you can verify on the GPhC register. Private treatment means no waiting list and no dependence on a devolved commissioning decision, but it is a genuine clinical process: a prescriber assesses your medical history, BMI, and any contraindications before anything is approved. Cost context is worth reading separately, the Eli Lilly price increase from September 2025 changed the private market significantly, with typical monthly costs varying by dose and provider.

Once a clinical assessment confirms suitability, the pen sits in your fridge at home (same shelf as everything else, 2–8°C) and you inject once a week, rotating sites as your prescriber advises. Travel or storage questions are always best directed to the Patient Information Leaflet or your prescriber.

What to do now if you're in Northern Ireland

If you're waiting for an NHS decision in Northern Ireland, the most useful thing is to keep your GP informed of your interest and ensure any qualifying conditions are documented in your records, that paper trail matters when commissioning criteria are eventually set. You can also check the broader NHS Mounjaro guidance for updates as they emerge.

If you'd rather not wait, a private clinical assessment is the next step. A GPhC-registered Independent Prescriber will review your consultation the same day, a real clinician, not an automated queue. Eligibility for private treatment follows the licensed criteria: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. Treatment is not suitable during pregnancy, breastfeeding or when trying to conceive, or for anyone under 18; a prescriber will cover all relevant contraindications as part of the consultation.

If you'd like to understand all the available options before deciding anything, the weight management treatment overview covers the landscape clearly. When you're ready to take the next step, you can start your free consultation and a prescriber will review your case the same day.